Heparin-induced thrombocytopenia: A critical risk/benefit analysis of patients in intensive care treated with r-hirudin

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 3, 2000, Pages 151-156

  Schenk, Joachim F ^a   Berg, Gunter ^a   Mörsdorf, Stefan ^a   Stefan, Bernhard ^a   Kroll, Hartmut ^b   Krischek, Boris ^a   Pindur, Gerhard ^a   Schieffer, Herrmann ^a   Wenzel, Ernst ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Evidence of benefit and risk; Heparin induced thrombocytopenia; High risk patients; Hirudin therapy

Indexed keywords

ALTEPLASE; HEPARIN; LEPIRUDIN; RECOMBINANT HIRUDIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK BENEFIT ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; CRITICAL CARE; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDIN THERAPY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PLATELET ACTIVATION; PLATELET COUNT; PROTHROMBIN TIME; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; RISK ASSESSMENT; THROMBOCYTOPENIA; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 0033845449     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600306     Document Type: Article

References (48)

1. The effect of commercial heparin on the platelet count
2. Arterial embolism occurring during systemic heparin therapy
3. Heparin - A cause of arterial emboli
4. Effect of heparin and heparin fractions on platelet aggregation
5. The mechanism of heparin-induced platelet aggregation
6. Heparin-induced thrombocytopenia - Diagnosis, natural history, and treatment options
7. Clinical presentation of heparin-induced thrombocytopenia
8. Immune-endothelial-cell injury in heparin-associated thrombocytopenia
9. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
10. Platelet factor 4-complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]
11. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
12. Immunologic studies in 1459 patients with clinically suspected heparin-induced thrombocytopenia
13. A diagnostic test for heparin-induced thrombocytopenia
14. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
15. Heparin-induced thrombocytopenia: Towards consensus
16. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
17. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis
18. The antigenic epitope in heparin-induced thrombocytopenia residues solely on platelet factor 4 [Abstract]
19. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin platelet factor 4 complexes
20. Heparin-induced thrombocytopenia: Laboratory studies
21. Insights into heparin-induced thrombocytopenia
22. On the role of platelet FcRIIa phenotype in heparin-induced thrombocytopenia
23. Heparin-associated thrombocytopenia: The antibody is not heparin specific
24. Presence of autoantibodies to interleukin-8- or neutral-activating peptide 2 in patients with heparin-associated thrombocytopenia
25. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
26. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia
27. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
28. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia
29. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls
30. Platelets of patients with peripheral arterial disease are hypersensitive to heparin
31. Thrombocytopenia associated with heparin-associated antiplatelet antibodies
32. Heparin-associated thrombocytopenia: A critical review and pooled analysis
33. The effect of secreted heparin-binding proteins on heparin binding to platelets
34. Heparin-induced platelet aggregation. II. Dose/response relationships for two molecular weight heparin fractions (CY 216 and Cy 222)
35. Heparinoide als eine Alternative for die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie
36. Allergische Reaktionen vom Spattyp auf Heparine
37. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
38. Clinical presentation of heparin-induced thrombocytopenia
39. Heparin-induced thrombocytopenia
40. Heparin-associated thrombocytopenia: An update
41. Heparin-induced thrombosis: An important complication of heparin prophylaxis for thromboembolic disease in surgery
42. Limitations of conventional treatment options for heparin-induced thrombocytopenia
43. HIPA versus PF4 ELISA for detecting heparin-induced thrombocytopenia
44. A recombinant hirudin in healthy volunteers. I. Effects on coagulation parameters and bleeding time
45. Uber die Steuerbarkeit subcutan und intravenos applizierter unterschiedlicher Dosierungen von r-Hirudin
46. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation
47. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO IIb)
48. A recombinant hirudin in healthy volunteers. II Effects on platelet adhesion and platelet induced thrombin generation time